{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:45:12Z","timestamp":1787985912746,"version":"build-2784847793"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T09:00:27Z","timestamp":1652173227000},"page":"393-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-0767","authenticated-orcid":false,"given":"Stephen","family":"Hawser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimmi","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-297X","authenticated-orcid":false,"given":"No\u00eblle","family":"Jemmely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowel","family":"Redder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.05.001_bib0001","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-014-0273-x","article-title":"Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia","volume":"74","author":"Syed","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2022.05.001_bib0002","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.45.3.825-836.2001","article-title":"In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci","volume":"45","author":"Hebeisen","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.05.001_bib0003","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00029-07","article-title":"Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae","volume":"51","author":"Davies","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.05.001_bib0004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jgar.2022.05.001_bib0005","unstructured":"International Organization for Standardization. Clinical laboratory testing and in vitro diagnostic test systems: susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776-1; 2006."},{"key":"10.1016\/j.jgar.2022.05.001_bib0006","unstructured":"The European Committee on Antimicrobial Susceptibility testing, 2019. Breakpoint tables for interpretation of MICs and zone diameters, version 9.0 http:\/\/www.eucast.org."},{"key":"10.1016\/j.jgar.2022.05.001_bib0007","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.02465-14","article-title":"Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jgar.2022.05.001_bib0008","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/jac\/dkaa306","article-title":"BSAC Resistance Surveillance Standing Committee. Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data","volume":"75","author":"Horner","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.05.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114978","article-title":"In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates","volume":"96","author":"Hawser","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.001_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","article-title":"Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.001_bib0011","unstructured":"Rossolini GM, Dryden MS, Kozloz RS, Quintana A, Flamm RK, et\u00a0al. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother 66:151\u20139."},{"key":"10.1016\/j.jgar.2022.05.001_bib0012","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2021.07.012","article-title":"Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories","volume":"26","author":"Hawser","year":"2021","journal-title":"J Global Antimicrob Res"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:45Z","timestamp":1761991245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":12,"alternative-id":["S2213716522001059"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.05.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}